In vitro safety pharmacology and secondary pharmacology both aim to de-risk drug candidates by identifying potential off-target effects before clinical development. Secondary pharmacology evaluates compound activity at non-primary targets that may contribute to adverse drug reactions, using broad in vitro panels that reflect key physiological systems. As regulatory expectations rise, in vitro profiling has become a critical component of early drug safety assessment, providing mechanistic insights, supporting candidate selection, and reducing late-stage attrition.
The theoretical foundation for safety-panel services is described in Reducing safety-related drug attrition: The use of in vitro pharmacological profiling ↗, published in Nature Reviews Drug Discovery in 2012. The publication highlights the value of identifying off-target activity early to reduce late-stage attrition.
The 2024 review The state of the art in secondary pharmacology and its impact on the safety of new medicines ↗summarizes insights from 18 major pharmaceutical companies. It highlights the limitations of binding-only assays and supports functional, dose–response-based profiling to better predict off-target risks and inform safer drug-development decisions.
Binding results do not necessarily indicate true functional activity and may overestimate the number of relevant hits.
Functional assays help reduce false positives and unnecessary follow-up testing.
Functional formats are better suited to detecting allosteric or agonist effects, particularly for ion-channel programs.
Relying on binding alone may miss important liabilities or lead to rejection of potentially useful compounds.
ICE Bioscience provides customizable in vitro functional safety panels for early off-target assessment and compound-specific risk evaluation.
ICE Bioscience provides Safety Pharmacology services with customizable panels tailored to specific drug-discovery needs. Our experts and broad portfolio of in vitro assays support compound-specific off-target evaluation and help advance safety decisions with greater confidence.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
Get a quote
Go top
